生物化学疗法治疗晚期肝癌的临床研究

The clinical study of biochemotherapy in treatment of advanced liver cancer

目的 比较生物化学疗法与单用化疗对晚期肝癌的疗效及观察其不良反应。方法 36例晚期肝癌患者随机分组接受生物化学疗法(A组)或单用化疗(B组)。A组:5-FU 375mg/m2 iv第1-5天,HCPT 6mg/m2 iv第1-5天,每3周重复,共2周期。化疗间歇期输注总数2-3×109个的TAK细胞。B组:单用化疗,方案同上。结果 A组有效率23.5％,B组有效率12.5％,(P>0.05)。A、B组主要不良反应分别为:白细胞减少(58.8％和62.5％)、血小板减少(17.6％和12.5％)、血红蛋白减少(35.3％和31.3％)、恶心呕吐(70.6％和68.8％)、脱发(29.4％和25％)、肝功损害(52.9％和43.8％)、肾功损害(5.8％和12.5％)、发热(29.4％和0％)和骨/肌肉酸痛(35.3％和0％)。发热、骨肌肉酸痛A组明显高于B组(P<0.05)。结论 生物化学疗法治疗晚期肝癌有效、安全,不良反应可以耐受。

To compare with the difference between biochemotherapy and chemotherapy in the efficacy and toxicity for treatment of patients with advanced liver cancer. Methods 36 patients with advanced liver cancer were randomized into A group or B group. A group recieved biochemotherapy 5 - FU 375mg/m2 iv d1-5, HCPT 6mg/m iv d1- 5, once every 3 weeks for 2 cycles. Interval time of chemotherapy re - infused TAK cells in tatal [ (2-3)×109]. B group recieved the same chemotherapy only. Results Overall response rate of A group was 23.5% , and B group 12.5% . ( P > 0.05). The main adverse effect A and B group were: leukopenia (58.8% vs62.5%); thrombocytopenia (17.6% vs 12.5%); anemia (35.3% vs31.3%); nausea/vomiting (70.6% vs 68.8%); alopecia (29.4% vs 25%); liver functional lesion (52.9% vs 43.8%); kidney functional lesion (5.8% vs 12.5%); fever (29.4% vs 0%) and bone/ muscle pain (35.3% vs 0%), respectively. But the incidence of fever and bone/ muscle pain was difference between this two group ( P < 0.05) . Conclusions The biochemotherapy in treatment of patients with advanced liver cancer is safety and efficiency. Overall toxicity was acceptable.